Kyowa Kirin Co., Ltd. (TYO:4151)
Japan · Delayed Price · Currency is JPY | Market Cap | 1.26T +6.1% |
| Revenue (ttm) | 482.21B -3.4% |
| Net Income | 36.57B -56.2% |
| EPS | 69.84 -55.4% |
| Shares Out | 523.49M |
| PE Ratio | 34.40 |
| Forward PE | 19.43 |
| Dividend | 60.00 (2.53%) |
| Ex-Dividend Date | Dec 29, 2025 |
| Volume | 1,478,000 |
| Average Volume | 1,437,120 |
| Open | 2,386.00 |
| Previous Close | 2,370.00 |
| Day's Range | 2,367.00 - 2,402.50 |
| 52-Week Range | 2,025.00 - 2,706.00 |
| Beta | 0.01 |
| RSI | 36.02 |
| Earnings Date | Feb 9, 2026 |
About Kyowa Kirin
Kyowa Kirin Co., Ltd. engages in the research, development, manufacture, import/export, and market of pharmaceuticals products worldwide. The company offers Crysvita, a recombinant human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23; POTELIGEO for the treatment of cutaneous T-cell lymphoma; Nouriast/Nourianz, an adenosine A2A receptor antagonist; G-LASTA, a mobilization of hematopoietic stem cells into peripheral blood for autologous blood stem cell transplantation; Libmeldy/Lenmeldy for treating metachro... [Read more]
Financial Performance
In 2024, Kyowa Kirin's revenue was 495.56 billion, an increase of 12.06% compared to the previous year's 442.23 billion. Earnings were 59.87 billion, a decrease of -26.26%.
Financial StatementsNews
Amgen (AMGN) Ends Collaboration with Kyowa Kirin on Roctinlimab
Amgen (AMGN) Ends Collaboration with Kyowa Kirin on Roctinlimab
Amgen ends collaboration agreement with Kyowa Kirin for eczema asset
Amgen ends roctinlimab deal with Kyowa Kirin, returning full rights. Read more here.
Kyowa Kirin Regains Global Rights To Atopic Dermatitis Drug After Amgen Collaboration Ends
Kyowa Kirin Co., Ltd . and Amgen Inc. (NASDAQ: AMGN) terminated on Friday the current rocatinlimab development and commercialization collaboration. • Amgen stock is trading at elevated levels. Where ...
Kyowa Kirin Regains Global Rights To Atopic Dermatitis Drug After Amgen Collaboration Ends
Kyowa Kirin Co., Ltd. and Amgen Inc. (NASDAQ: AMGN) terminated on Friday the current rocatinlimab development and commercialization collaboration.
Amgen Inc. (AMGN) Announces Termination of License and Collaboration Agreement with Kyowa Kirin
Amgen Inc. (AMGN) Announces Termination of License and Collaboration Agreement with Kyowa Kirin
Amgen, Kyowa Kirin End Collaboration On Atopic Dermatitis Drug Rocatinlimab
(RTTNews) - Kyowa Kirin Co., Ltd. (KYKOY) said on Friday it has ended its development and commercialization partnership with Amgen for rocatinlimab, with the Japanese drugmaker regaining full control ...
Amgen (AMGN) Ends Collaboration with Kyowa Kirin on Rocatinlimab
Amgen (AMGN) Ends Collaboration with Kyowa Kirin on Rocatinlimab
Kyowa Kirin announces management changes
Kyowa Kirin Announces Proposed Appointment of Abdul Mullick to President and Chief Executive Officer, While Former CEO Masashi Miyamoto to Remain Chairman
TOKYO--(BUSINESS WIRE)--Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), a Japan-based global specialty pharmaceutical company, today announced the Board of Directors' decision to appoint Abdul Mullick,...
Kura Oncology, Kyowa Kirin reveal Komsifti combo data for AML
First Commercial Sale Of KOMZIFTI In U.S. Triggers $135 Million Milestone Payment To Kura
(RTTNews) - Kura Oncology, Inc. (KURA) is all set to receive a $135 million milestone payment from its partner Kyowa Kirin, following the first U.S. commercial sale of KOMZIFTI.
Kyowa Kirin to Present New Research Highlighting Mogamulizumab's Clinical Utility and Strategic Potential in T-Cell Lymphomas at 2025 ASH Annual Meeting
Princeton, NJ, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Kyowa Kirin, Inc., a wholly owned subsidiary of Kyowa Kirin Co. Ltd (TSE: 4151), today announced new clinical study data spotlighting the potential for...
Kyowa Kirin to Present New Research Highlighting Mogamulizumab's Clinical Utility and Strategic Potential in T-Cell Lymphomas at 2025 ASH Annual Meeting
Princeton, NJ, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Kyowa Kirin, Inc., a wholly owned subsidiary of Kyowa Kirin Co. Ltd (TSE: 4151), today announced new clinical study data spotlighting the potential for...
Kura Oncology wins FDA approval for leukemia drug
Kura Oncology (KURA) stock is in focus as FDA approves the company's leukemia drug Komzifti developed with Kyowa Kirin (KYKOF). Read more here.
Kyowa Kirin International Announces Appointment of Julie Dehaene-Puype as President for the Region
GALASHIELS, Scotland & MARLOW, England--(BUSINESS WIRE)--Kyowa Kirin International (“KKI”), a group company of Kyowa Kirin Co., Ltd. (TSE:4151, “Kyowa Kirin”), a Japan-based Global Specialty Pharmaceu...
Kyowa Kirin reports 9M results
Boehringer Ingelheim acquires license from Kyowa Kirin aimed at developing a novel treatment for patients with autoimmune diseases
The licensed small molecule program aims to address significant unmet needs for autoimmune diseases . Program adds to Boehringer's pipeline and its commitment to deliver breakthrough therapies for pa...
Kyowa Kirin and Orchard Therapeutics Announce OTL-200 Granted Orphan Regenerative Medicine Product Designation for Early-onset MLD in Japan
– First and only disease-modifying therapy for the treatment of eligible children with MLD also receives Orphan Drug Designation and Priority Review in the Kingdom of Saudi Arabia – – First and only d...
Kura Oncology Scores $30 Million Boost As New Leukemia Drug Enters Major Trial
Kura Oncology, Inc. (NASDAQ: KURA) shares rose Friday after the biotechnology firm confirmed a $30 million milestone payment from its collaboration with Kyowa Kirin . The payment followed the first p...
Kura Oncology Transitioning To Commercial Stage: Why I Choose To Buy
Kura Oncology is rated Buy, driven by a strong cash position, strategic Kyowa Kirin partnership, and a robust, diversified pipeline. Learn more about KURA stock here.
Amgen Rocatinlimab's Data Shows Potential As Long-Term Therapy For Atopic Dermatitis
Amgen Inc. (NASDAQ: AMGN) and Kyowa Kirin released preliminary topline results from the ASCEND study evaluating rocatinlimab in adults and adolescents with moderate to severe atopic dermatitis (AD) o...
Amgen (AMGN) and Kyowa Kirin Report Positive Long-term Results for Rocatinlimab
Amgen (AMGN) and Kyowa Kirin Report Positive Long-term Results for Rocatinlimab
Amgen, Kyowa Kirin announce long-term Phase 3 data for eczema drug
Amgen Inc (AMGN) and Kyowa Kirin Announce Promising Results from ASCEND Study on Rocatinlimab ...
Amgen Inc (AMGN) and Kyowa Kirin Announce Promising Results from ASCEND Study on Rocatinlimab for Atopic Dermatitis | AMGN stock news
Amgen Inc (AMGN) and Kyowa Kirin Announce Promising Results from Rocatinlimab Phase 3 ASCEND ...
Amgen Inc (AMGN) and Kyowa Kirin Announce Promising Results from Rocatinlimab Phase 3 ASCEND Study | AMGN stock news